If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Corresponding author at: Laura Schwarz-Kipp Research of Autoimmune Diseases, Sackler School, of Medicine Tel-Aviv University, Neuroimmunology Laboratory, Multiple Sclerosis Center, Sheba Medical Center, Israel.
The most effective approach to fight COVID-19 infection is prevention by targeted vaccines that prime the immune system prior to a first encounter with the virus. The BNT162b2 messenger RNA (mRNA) vaccine encoding the SARS-CoV-2 full length spike generates antibodies that prevent the entry of the virus into cells by blocking either ACE2–RBD binding interactions or spike-mediated membrane fusion [
]. As the process of vaccination against COVID-19 is currently spreading all over the world, it is of importance to assess the longevity of the humoral immune response to the vaccination. A high percentage of protective antibody responses was reported 7 days after full vaccination with BNT162b2 [
]. To better understand the longevity of the humoral response, we conducted a prospective longitudinal study among a cohort of healthy vaccinees up to eight months from the second vaccine dose. The study was approved by Sheba Medical Center Institutional Review Board (approval number Sheba.SMC-8182-21), and all participants signed written informed consent. All participants had no prior infection with SARS-CoV-2, and no evidence of infection during the study. Subjects received two PfizerBNT162b2 vaccine doses, 21 days apart, delivered in the deltoid muscle. SARS-CoV-2 anti-spike IgG levels were measured at least 28 days following the second vaccine dose at two or more time points and spike IgG titer average t1/2 was calculated using linear regression from log2-transformed data for each pair, according to the following equation t1/2=Elapsed time*log2/log[Beginning amount/Ending amount]. Immunoassay for the detection of SARS-CoV-2 IgG antibodies was performed using anti-SARS-CoV-2 QuantiVac ELISA IgG (Euroimmun, Lubeck, Germany) based on the S1 domain of the spike protein. Cut-off for positive IgG level was determined as >35.2 binding antibody units (BAU)/ml. The test has a sensitivity of 93.2% % and a specificity of 100%. Correlation with neutralization tests was reported to be 98.2% (https://www.euroimmun.de/en/).
Thirty-nine vaccinated subjects, 9 males, 30 females, mean±SD age 54.3±15.24 years, median 57.8 years, range 25.9-89.0 years, followed for median 4.3 months, range 1.0 - 8.3 months after the second vaccine dose, were included in the study. The time interval between the first and second paired IgG tests was median 83 days, (25 IQR-75 IQR) 64-98 days, range 20 to 142 days. Spike IgG titers (BAU/ml) were heterogeneous among subjects, median 921, (25 IQR-75 IQR) 505–1376, range 19.2-3840.0). The decline from the first to the second time point in spike IgG titers (BAU/ml) was median 617.6, (25 IQR-75 IQR) 300.8-960.0, range 12.8-2764.8). Fig. 1 demonstrates the durability of paired assessments of circulating antibody titers based on data ≥28 days post the second vaccine dose. The antibody responses decay kinetics showed median t1/2 of 45 days, (25 IQR-75 IQR) 38.2-62.3 days. SARS-CoV-2 IgG titers inversely correlated with age (r= -0.323), and SARS-CoV-2 IgG decline corrected for baseline level correlated with age ≥60 years (r= 0.277), while in younger subjects <60 years an inverse correlation was observed (r= -0.502). No significant differences were observed in the decay kinetics in relation with gender. Our findings demonstrate that anti-S1 IgG levels determined across 1 to 8 months after full vaccination, waned with an estimated half-life of 45 days. Age was associated with lower post-vaccination anti-S1 IgG titers and with accelerated IgG decrease over time. Moreover, we calculated that within 225 days (5*t1/2), IgG will decrease below detection level, raising the need for reconsidering the current mRNA vaccine regiments. In comparison, seasonal coronavirus protective immunity in convalescents was reported to be similarly short-lasting up to one year [
The question of long‐lasting and protective vaccine immunity against SARS‐CoV‐2 is of major importance as the decay suggests the need for an additional booster. A decrease in IgG levels impairs the equilibrium between COVID-19 viral load during exposure and humoral protection. The induction and decay of antigen-specific IgG response to COVID-19 mRNA vaccine are consistent with the known serum T½ of various IgG subclasses immunoglobulin [
]. Older vaccinees, aged ≥ 60 years, demonstrated a more profound decrease in IgG levels over time and are therefore at increased risk for infection with COVID-19 and COVID-19 variants. The Israeli healthcare authorities in accordance recently launched the third vaccination booster in people older than 60 years of age.
CRediT authorship contribution statement
Anat Achiron: Data curation, Funding acquisition, Writing – original draft, Funding acquisition, Writing – review & editing. Mathilda Mandel: Conceptualization, Data curation, Writing – original draft, Writing – review & editing. Sapir Dreyer-Alster: Visualization, Software, Data curation, Writing – review & editing. Gil Harari: Formal analysis, Data curation, Writing – review & editing. Michael Gurevich: Data curation, Supervision, Writing – review & editing.
Declaration of Competing Interest
Anat Achiron, MD, PhD - no conflicts of interest.Mathilda Mandel, MD, MHA - no conflicts of interest. Sapir Dreyer-Alster, BSc - no conflicts of interest Gil Harari, PhD - no conflicts of interest. Michael Gurevich - no conflicts of interest.
This work was funded by research grants from the Sheba Medical Center (GN. 04027-10/1001493 ), and the Laura Schwarz-Kipp Research Fund for Autoimmune Diseases (GN. 0601253231 ), Sackler School of Medicine , Tel-Aviv University , Israel.
BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2.